newsfilter
← Latest News
GlobeNewswire·

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines,